This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Erythropoietin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Erythropoietin is a haemopoietic glycoprotein growth factor derived from a single gene on chromosome seven which is expressed in cells of the renal cortex. Some 10% is produced by the liver by unknown cells; this amount is not enough for normal functioning. Its key action is to control erythropoiesis.

Normally erythropoietin is produced as a result hypoxia detected by an oxygen sensor; it then acts back on an effector receptor. There is normally a rise in levels in anaemia.

Recombinant erythropoietin is clinically useful in a range of conditions including chronic renal failure. It must be grown in mammalian cell lines so that proper glycosylation can occur.

Notes:

  • there are concerns about using erythopoietin in patients with cancer:
    • study evidence revealed that erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.